# PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

> **NCT05737563** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 380 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma Abdominal Stage 0

## Interventions

- **DRUG:** PD-1 Inhibitors
- **DRUG:** Irinotecan
- **DRUG:** Capecitabine tablets

## Key facts

- **NCT ID:** NCT05737563
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-17
- **Primary completion:** 2026-02-17
- **Final completion:** 2026-02-17
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737563, "PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05737563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*